“GENDER-BASED ANALYSIS OF ADVERSE EFFECTS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES: A COMPARATIVE ”. Global Science Review, vol. 2, no. 1, Mar. 2025, pp. 418-22, https://global-science-review.com/ojs/index.php/gsr/article/view/238.